

ABSTRACT OF THE DISCLOSURE

Anti-hormonal (anti-estrogenic steroid) therapy and immunotherapy are used in combination to treat breast cancer. The preferred immunotherapeutic agent is an
5 immunogen, preferably comprising sialyl-Tn, and more preferably is a sialyl-Tn/KLH conjugate.